Expression of androgen receptor splice variants in clinical breast cancers

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44728-44744

  Hickey, Theresa E ^a   Irvine, Connie M ^a   Dvinge, Heidi ^b,c   Tarulli, Gerard A ^a   Hanson, Adrienne R ^a   Ryan, Natalie K ^a   Pickering, Marie A ^a   Birrell, Stephen N ^a   Hu, Dong Gui ^d   Mackenzie, Peter I ^d   Russell, Roslin ^e   Caldas, Carlos ^e   Raj, Ganesh V ^f   Dehm, Scott M ^g,h   Plymate, Stephen R ⁱ   Bradley, Robert K ^b,c   Tilley, Wayne D ^a   Selth, Luke A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Division of Public Health Sciences   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d FLINDERS UNIVERSITY   (Australia)

^e CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alternative splicing; Androgen deprivation therapy; Androgen receptor; Biomarker; Breast cancer

Indexed keywords

ANDROGEN RECEPTOR; ENZALUTAMIDE; TRANSCRIPTOME; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AR PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; ISOPROTEIN; MESSENGER RNA; PHENYLTHIOHYDANTOIN;

ALTERNATIVE RNA SPLICING; ANDROGEN DEPRIVATION THERAPY; AR GENE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; EX VIVO STUDY; EXON; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; TRANSCRIPTION REGULATION; ANALOGS AND DERIVATIVES; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MCF-7 CELLS; PHENYLTHIOHYDANTOIN; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84953449870     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6296     Document Type: Article

References (67)

1. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple- negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109:1721-1728.
2. Hudis CA and Gianni L. Triple-negative breast cancer: an unmet medical need. The oncologist. 2011; 16:1-11.
3. Green SM, Mostaghel EA and Nelson PS. Androgen action and metabolism in prostate cancer. Molecular and cellular endocrinology. 2012; 360:3-13.
4. Hickey TE, Robinson JL, Carroll JS and Tilley WD. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Molecular endocrinology. 2012; 26:1252-1267.
5. Agoff SN, Swanson PE, Linden H, Hawes SE and Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. American journal of clinical pathology. 2003; 120:725-731.
6. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW and Lee KS. Expression of androgen receptors in primary breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2010; 21:488-492.
7. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ and Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995; 52:459-467.
8. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C and Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006; 25:3994-4008.
9. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M and Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005; 24:4660-4671.
10. Hall RE, Birrell SN, Tilley WD and Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. European journal of cancer. 1994; 30A:484-490.
11. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121:2750-2767.
12. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG and Carroll JS. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. The EMBO journal. 2011; 30:3019-3027.
13. Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS and Brown M. Amplitude modulation of androgen signaling by c-MYC. Genes & development. 2013; 27:734-748.
14. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS and Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011; 20:119-131.
15. Naderi A and Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 2008; 10:542-548.
16. Scher HI, Buchanan G, Gerald W, Butler LM and Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004; 11:459-476.
17. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG and Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10:33-39.
18. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR and Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res. 2001; 7:1273-1281.
19. Haile S and Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci. 2011; 68:3971-3981.
20. Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, Butler LM, Marshall VR, Scher HI, Gerald WL, Coetzee GA and Tilley WD. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res. 2007; 67:10087-10096.
21. Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I, Helin HJ, Janne OA, Vihinen M, Palvimo JJ and Koivisto PA. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest. 2002; 82:1591-1598.
22. Cai C and Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011; 18:R175-182.
23. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A. 1995; 92:3439-3443.
24. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W and Greenberg NM. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A. 2005; 102:1151-1156.
25. Buchanan G, Need EF, Bianco-Miotto T, Greenberg NM, Scher HI, Centenera MM, Butler LM, Robins DM and Tilley WD. (2009). Insights from AR gene mutations. In: Tindall DJ and Mohler JL, eds. Androgen action in prostate cancer. (New York: Springer), pp. 207-240.
26. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL and Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008; 68:5469-5477.
27. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J and Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009; 69:2305-2313.
28. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS and Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69:16-22.
29. Dehm SM and Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011; 18:R183-196.
30. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA and Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013; 73:483-489.
31. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A and Wikstrom P. Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival. PLoS One. 2011; 6:e19059.
32. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS and Plymate SR. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010; 120:2715-2730.
33. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K and Sawyers CL. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A. 2010; 107:16759-16765.
34. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371:1028-1038.
35. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486:346-352.
36. Tress ML, Martelli PL, Frankish A, Reeves GA, Wesselink JJ, Yeats C, Olason PI, Albrecht M, Hegyi H, Giorgetti A, Raimondo D, Lagarde J, Laskowski RA, Lopez G, Sadowski MI, Watson JD, et al. The implications of alternative splicing in the ENCODE protein complement. Proc Natl Acad Sci U S A. 2007; 104:5495-5500.
37. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP and Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008; 456:470-476.
38. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, Williams BA, Zaleski C, Rozowsky J, et al. Landscape of transcription in human cells. Nature. 2012; 489:101-108.
39. Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, Birrell SN, Butler LM, Hickey TE and Tilley WD. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr Relat Cancer. 2012; 19:599-613.
40. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR and Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012; 72:3457-3462.
41. Dutertre M, Gratadou L, Dardenne E, Germann S, Samaan S, Lidereau R, Driouch K, de la Grange P and Auboeuf D. Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer. Cancer Res. 2010; 70:3760-3770.
42. Ringner M, Fredlund E, Hakkinen J, Borg A and Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One. 2011; 6:e17911.
43. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J and Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004; 6:517-527.
44. Risbridger GP, Davis ID, Birrell SN and Tilley WD. Breast and prostate cancer: more similar than different. Nature reviews Cancer. 2010; 10:205-212.
45. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E and Dong X. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2013.
46. Chan SC and Dehm SM. Constitutive activity of the androgen receptor. Advances in pharmacology. 2014; 70:327-366.
47. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M and Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011; 20:457-471.
48. Pihlajamaa P, Sahu B, Lyly L, Aittomaki V, Hautaniemi S and Janne OA. Tissue-specific pioneer factors associate with androgen receptor cistromes and transcription programs. The EMBO journal. 2014; 33:312-326.
49. Chang C, Lee SO, Yeh S and Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014; 33:3225-3234.
50. Hu DG, Hickey TE, Irvine C, Wijayakumara DD, Lu L, Tilley WD, Selth LA and Mackenzie PI. Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues. Hormones & cancer. 2014.
51. Katz Y, Wang ET, Airoldi EM and Burge CB. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nature methods. 2010; 7:1009-1015.
52. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, Sloan CA, Rosenbloom KR, Roe G, Rhead B, Raney BJ, Pohl A, Malladi VS, Li CH, Lee BT, Learned K, et al. The UCSC Genome Browser database: extensions and updates 2013. Nucleic acids research. 2013; 41:D64-69.
53. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fairley S, Fitzgerald S, Gil L, Garcia-Giron C, Gordon L, Hourlier T, Hunt S, et al. Ensembl 2013. Nucleic acids research. 2013; 41:D48-55.
54. Langmead B, Trapnell C, Pop M and Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10:R25.
55. Li B and Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC bioinformatics. 2011; 12:323.
56. Trapnell C, Pachter L and Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009; 25:1105-1111.
57. Robinson MD and Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010; 11:R25.
58. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:1160-1167.
59. Mediwala SN, Sun H, Szafran AT, Hartig SM, Sonpavde G, Hayes TG, Thiagarajan P, Mancini MA and Marcelli M. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. The Prostate. 2012.
60. Chan SC, Li Y and Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem. 2012; 287:19736-19749.
61. Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA and Tilley WD. Structural and functional consequences of glutamine tract variation in the androgen receptor. Human molecular genetics. 2004; 13:1677-1692.
62. Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM and Tilley WD. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 2005; 65:8487-8496.
63. Koh CM. Preparation of cells for microscopy using cytospin. Methods in enzymology. 2013; 533:235-240.
64. Tarulli GA, De Silva D, Ho V, Kunasegaran K, Ghosh K, Tan BC, Bulavin DV and Pietersen AM. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium. Breast cancer research: BCR. 2013; 15:R10.
65. Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD and Butler LM. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget. 2013; 4:691-704.
66. Zivadinovic D and Watson CS. Membrane estrogen receptor- alpha levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast cancer research: BCR. 2005; 7:R130-144.
67. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK and Knudsen ES. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell cycle. 2012; 11:2756-2761.